WASF2 and adrenal cortex carcinoma: The KM results demonstrated that patients with higher WASF2 expression had a poorer PFI compared to patients with lower WASF2 levels in ACC (P < 0.001), BLCA (P = 0.295), KICH (P = 0.147), LGG (P < 0.001), LIHC (P = 0.035) and OV (P = 0.005), while patients with increased WASF2 levels showed a superior PFI than those with decreased WASF2 levels in HNSC (P = 0.025), KIRC (P = 0.017), THYM (P = 0.051) and UVM (P = 0.055), as shown in Figures 4B–K.